SARS-CoV-2 - Acalabrutinib - Candidats thérapeutiques

SARS-CoV-2 - Acalabrutinib - Candidats thérapeutiques


Acalabrutinib (or Calquence) is an inhibitor of Bruton's tyrosine kinase (BTK). By inactivating the BTK, acalabrutinib prevents activation of the B-cell antigen receptor (BCR) signaling pathway. The B cell activation and downstream survival pathways of B-cells are thus inhibited and, as a result, the growth of malignant B cells that overexpress B-cells is inhibited. It is for this mode of action that acalabrutinib is used in the treatment of certain types of non-Hodgkin's lymphoma such as mantle cell lymphoma.
A clinical trial is planned to evaluate the effect of acalabrutinib (Calquence) on the exaggerated immune response in patients with severe coronavirus 2019 infection (Covid-19). This clinical study was based on preliminary scientific and clinical data on the BTK pathway and its role in the production of inflammatory cytokines. The purpose of the study was to evaluate the efficacy of acalabrutinib in reducing mortality and ventilation support requirements for patients with severe symptoms of Covid-19.

Search result : 81 product found

Refine your search :

RUOCE / IVD
  • Unconjugated 30
  • human 2
  • Biochemicals 41
  • Inhibitor/Antagonist/Agonist 40
  • Chromatography 3


Cat#
Description
Cond.
Price Bef. VAT
HY-17600S-1mg
 1mg 
HY-17600-5mg
 5mg 
HY-17600-100mg
 100mg 
HY-17600-50mg
 50mg 
HY-17600-10mg
 10mg 
HY-17600-200mg
 200mg 
HY-17600-1ml
 10mM*1mL 
orb636843-5mg
 5mg 
orb610615-5mg
 5mg 
orb610615-100mg
 100mg 
orb610615-25mg
 25mg 
orb636843-25mg
 25mg 
orb638841-25mg
 25mg 
orb638841-50mg
 50mg 
orb638841-200mg
 200mg 
orb638841-100mg
 100mg 
orb638841-500mg
 500mg 
orb638841-1g
 1g 
orb762788-25mg
 25mg 
orb762788-5mg
 5mg